Enhancing cancer immunotherapy with nanomedicine

[1]  R. Weichselbaum,et al.  Tumor-reprogrammed resident T cells resist radiation to control tumors , 2019, Nature Communications.

[2]  S. Paris,et al.  DNA damage enhancement by radiotherapy-activated hafnium oxide nanoparticles improves cGAS-STING pathway activation in human colorectal cancer cells. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[3]  P. Ágoston,et al.  NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial. , 2019, The Lancet. Oncology.

[4]  N. Jahchan,et al.  Tuning the Tumor Myeloid Microenvironment to Fight Cancer , 2019, Front. Immunol..

[5]  D. Irvine,et al.  Enhanced CAR–T cell activity against solid tumors by vaccine boosting through the chimeric receptor , 2019, Science.

[6]  M. King,et al.  Minimal dosing of leukocyte targeting TRAIL decreases triple-negative breast cancer metastasis following tumor resection , 2019, Science Advances.

[7]  L. Joosten,et al.  Therapeutic targeting of trained immunity , 2019, Nature Reviews Drug Discovery.

[8]  Zhenghan Di,et al.  NIR-light-mediated spatially selective triggering of anti-tumor immunity via upconversion nanoparticle-based immunodevices , 2019, Nature Communications.

[9]  M. Hurwitz,et al.  A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors. , 2019, Cancer discovery.

[10]  S. Thomas,et al.  Material design for lymph node drug delivery , 2019, Nature Reviews Materials.

[11]  S. Jagannath,et al.  Anti‐BCMA CAR T‐Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma , 2019, The New England journal of medicine.

[12]  R. Jain,et al.  Reprogramming the microenvironment with tumor-selective angiotensin blockers enhances cancer immunotherapy , 2019, Proceedings of the National Academy of Sciences.

[13]  R. Weichselbaum,et al.  Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors , 2019, Nature Communications.

[14]  M. Merad,et al.  Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination , 2019, Nature Medicine.

[15]  D. Irvine,et al.  Redox-responsive interleukin-2 nanogel specifically and safely promotes the proliferation and memory precursor differentiation of tumor-reactive T-cells. , 2019, Biomaterials science.

[16]  D. Neri.  Antibody–Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity , 2019, Cancer Immunology Research.

[17]  S. Kent,et al.  Immunological basis for enhanced immunity of nanoparticle vaccines , 2019, Expert review of vaccines.

[18]  M. Garcia‐Fuentes,et al.  Co‐delivery of RNAi and chemokine by polyarginine nanocapsules enables the modulation of myeloid‐derived suppressor cells , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[19]  K. Burke,et al.  Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs , 2019, Science Translational Medicine.

[20]  K. Wittrup,et al.  What, Why, Where, and When: Bringing Timing to Immuno-Oncology. , 2019, Trends in immunology.

[21]  Mark Kelley,et al.  Endosomolytic Polymersomes Increase the Activity of Cyclic Dinucleotide STING Agonists to Enhance Cancer Immunotherapy , 2018, Nature Nanotechnology.

[22]  Wenbin Lin,et al.  Nanoparticle-Mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy. , 2018, Angewandte Chemie.

[23]  Yan Shi,et al.  Precise Spatiotemporal Interruption of Regulatory T-cell-Mediated CD8+ T-cell Suppression Leads to Tumor Immunity. , 2018, Cancer research.

[24]  Quanyin Hu,et al.  In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment , 2018, Nature Nanotechnology.

[25]  Miles A. Miller,et al.  Quantitative Imaging of Tumor-Associated Macrophages and Their Response to Therapy Using 64Cu-Labeled Macrin. , 2018, ACS nano.

[26]  Kristy M Ainslie,et al.  A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer. , 2018, JCI insight.

[27]  C. Mirkin,et al.  RNA-Based Immunostimulatory Liposomal Spherical Nucleic Acids as Potent TLR7/8 Modulators. , 2018, Small.

[28]  P. Ascierto,et al.  Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT) , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  R. Emerson,et al.  Radiotherapy induces responses of lung cancer to CTLA-4 blockade , 2018, Nature Medicine.

[30]  E. Gilboa,et al.  An RNA toolbox for cancer immunotherapy , 2018, Nature Reviews Drug Discovery.

[31]  H. Kaufman,et al.  Integrating oncolytic viruses in combination cancer immunotherapy , 2018, Nature Reviews Immunology.

[32]  Michel Sadelain,et al.  Chimeric Antigen Receptor Therapy. , 2018, The New England journal of medicine.

[33]  Shiladitya Sengupta,et al.  A designer self-assembled supramolecule amplifies macrophage immune responses against aggressive cancer , 2018, Nature Biomedical Engineering.

[34]  B. Nelson,et al.  Oncolytic viruses as engineering platforms for combination immunotherapy , 2018, Nature Reviews Cancer.

[35]  P. L. La Riviere,et al.  Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy , 2018, Nature Communications.

[36]  Li Tang,et al.  Enhancing T cell therapy through TCR signaling-responsive nanoparticle drug delivery , 2018, Nature Biotechnology.

[37]  Leaf Huang,et al.  Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap , 2018, Nature Communications.

[38]  Andrew Z. Wang,et al.  A Dual Immunotherapy Nanoparticle Improves T‐Cell Activation and Cancer Immunotherapy , 2018, Advanced materials.

[39]  Michael F. Cuccarese,et al.  TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. , 2018, Nature biomedical engineering.

[40]  Zhijian J. Chen,et al.  The cGAS–cGAMP–STING pathway connects DNA damage to inflammation, senescence, and cancer , 2018, The Journal of experimental medicine.

[41]  M. Amiji,et al.  Repolarization of Tumor-Associated Macrophages in a Genetically Engineered Nonsmall Cell Lung Cancer Model by Intraperitoneal Administration of Hyaluronic Acid-Based Nanoparticles Encapsulating MicroRNA-125b. , 2018, Nano letters.

[42]  Jennifer A. Rohrs,et al.  CAR-T Cells Surface-Engineered with Drug-Encapsulated Nanoparticles Can Ameliorate Intratumoral T-cell Hypofunction , 2018, Cancer Immunology Research.

[43]  Fabian Kiessling,et al.  Tumor targeting via EPR: Strategies to enhance patient responses. , 2018, Advanced drug delivery reviews.

[44]  Michael F. Cuccarese,et al.  TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy , 2018, Nature Biomedical Engineering.

[45]  Frank A. Veliz,et al.  Treatment of Canine Oral Melanoma with Nanotechnology-Based Immunotherapy and Radiation. , 2018, Molecular pharmaceutics.

[46]  C. Yee.  Adoptive T cell therapy: points to consider. , 2018, Current opinion in immunology.

[47]  S. Son,et al.  Elimination of established tumors with nanodisc-based combination chemoimmunotherapy , 2018, Science Advances.

[48]  C. Pelizzari,et al.  Low-dose X-ray radiotherapy–radiodynamic therapy via nanoscale metal–organic frameworks enhances checkpoint blockade immunotherapy , 2018, Nature Biomedical Engineering.

[49]  Omkar U. Kawalekar,et al.  CAR T cell immunotherapy for human cancer , 2018, Science.

[50]  Jamie B. Spangler,et al.  Reprogramming immune proteins as therapeutics using molecular engineering , 2018 .

[51]  J. Schneck,et al.  Separating T Cell Targeting Components onto Magnetically Clustered Nanoparticles Boosts Activation. , 2018, Nano letters.

[52]  I. Melero,et al.  Radiation effects on antitumor immune responses: current perspectives and challenges , 2018, Therapeutic advances in medical oncology.

[53]  Matthew D. Hellmann,et al.  Immune‐Related Adverse Events Associated with Immune Checkpoint Blockade , 2018, The New England journal of medicine.

[54]  D. Irvine,et al.  Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity , 2018, Nature Communications.

[55]  H. Shroff,et al.  Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy , 2017, Nature Communications.

[56]  R. Weichselbaum,et al.  Host STING-dependent MDSC mobilization drives extrinsic radiation resistance , 2017, Nature Communications.

[57]  Gordon J. Freeman,et al.  T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity , 2017, Nature Communications.

[58]  Q. Luo,et al.  Molecular-Targeted Immunotherapeutic Strategy for Melanoma via Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages. , 2017, ACS nano.

[59]  B. Stoddard,et al.  Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers , 2017, Nature Communications.

[60]  W. Rubas,et al.  Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy , 2017, PloS one.

[61]  C. N. Coleman,et al.  DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity , 2017, Nature Communications.

[62]  Miles A. Miller,et al.  Radiation therapy primes tumors for nanotherapeutic delivery via macrophage-mediated vascular bursts , 2017, Science Translational Medicine.

[63]  Tian Zhang,et al.  Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy , 2017, Nature Nanotechnology.

[64]  A. Kaifer,et al.  4PD Functionalized Dendrimers: A Flexible Tool for In Vivo Gene Silencing of Tumor-Educated Myeloid Cells , 2017, The Journal of Immunology.

[65]  Betty Y. S. Kim,et al.  Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy. , 2017, Nature nanotechnology.

[66]  Matthias T Stephan,et al.  In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. , 2017, Nature nanotechnology.

[67]  Zhijian J. Chen,et al.  A STING-Activating Nanovaccine for Cancer Immunotherapy , 2017, Nature nanotechnology.

[68]  Li Tang,et al.  Enhancing Adoptive Cell Therapy of Cancer through Targeted Delivery of Small-Molecule Immunomodulators to Internalizing or Noninternalizing Receptors. , 2017, ACS nano.

[69]  N. Tinari,et al.  Intratumoral Delivery of Immunotherapy—Act Locally, Think Globally , 2017, The Journal of Immunology.

[70]  P. Kantoff,et al.  Cancer nanomedicine: progress, challenges and opportunities , 2016, Nature Reviews Cancer.

[71]  R. Weichselbaum,et al.  Photodynamic Therapy Mediated by Nontoxic Core-Shell Nanoparticles Synergizes with Immune Checkpoint Blockade To Elicit Antitumor Immunity and Antimetastatic Effect on Breast Cancer. , 2016, Journal of the American Chemical Society.

[72]  Yichao Chen,et al.  An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy , 2016, Nature Communications.

[73]  Morteza Mahmoudi,et al.  Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. , 2016, Nature nanotechnology.

[74]  H. Kohrt,et al.  Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer. , 2016, Cancer research.

[75]  Ralph R. Weichselbaum,et al.  Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy , 2016, Nature Communications.

[76]  L. Zitvogel,et al.  Trial Watch: Immunotherapy plus radiation therapy for oncological indications , 2016, Oncoimmunology.

[77]  A. Ray,et al.  A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma , 2016, Oncotarget.

[78]  E. Lavelle,et al.  Modulation of Immune Responses by Particulate Materials , 2016, Advanced materials.

[79]  J. Benoit,et al.  Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy. , 2016, Biomaterials.

[80]  K. Thurecht,et al.  Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date , 2016, Pharmaceutical Research.

[81]  Özlem Türeci,et al.  Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy , 2016, Nature.

[82]  N. Magné,et al.  Nanoparticles in radiation oncology: From bench-side to bedside. , 2016, Cancer letters.

[83]  A. J. Tavares,et al.  Analysis of nanoparticle delivery to tumours , 2016 .

[84]  R. Xavier,et al.  Trained immunity: A program of innate immune memory in health and disease , 2016, Science.

[85]  M. Addepalli,et al.  NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models , 2016, Clinical Cancer Research.

[86]  P. Lizotte,et al.  In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer , 2015, Nature nanotechnology.

[87]  Takashi Nakamura,et al.  Liposomes loaded with a STING pathway ligand, cyclic di-GMP, enhance cancer immunotherapy against metastatic melanoma. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[88]  Ralph Weissleder,et al.  Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug , 2015, Nature Communications.

[89]  S. Turley,et al.  Immunological hallmarks of stromal cells in the tumour microenvironment , 2015, Nature Reviews Immunology.

[90]  Fernando Torres Andón,et al.  Nanomedicine and cancer immunotherapy – targeting immunosuppressive cells , 2015, Journal of drug targeting.

[91]  R. Hollingsworth,et al.  Doxil Synergizes with Cancer Immunotherapies to Enhance Antitumor Responses in Syngeneic Mouse Models , 2015, Neoplasia.

[92]  Bret D Ulery,et al.  Nanoparticles as synthetic vaccines. , 2015, Current opinion in biotechnology.

[93]  Bryan Hoang,et al.  Docetaxel-carboxymethylcellulose nanoparticles target cells via a SPARC and albumin dependent mechanism. , 2015, Biomaterials.

[94]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[95]  D. Irvine,et al.  Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells , 2015, Science Translational Medicine.

[96]  A. Olivi,et al.  Uniform brain tumor distribution and tumor associated macrophage targeting of systemically administered dendrimers. , 2015, Biomaterials.

[97]  D. Hedley,et al.  Targeting of metastasis-promoting tumor-associated fibroblasts and modulation of pancreatic tumor-associated stroma with a carboxymethylcellulose-docetaxel nanoparticle. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[98]  J. Hubbell,et al.  6-Thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells and enhance the efficacy of T cell immunotherapy in tumor-bearing mice , 2015, Cancer Immunology, Immunotherapy.

[99]  David C. Smith,et al.  Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  R. Bourgon,et al.  Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display , 2015, Proceedings of the National Academy of Sciences.

[101]  C. Mirkin,et al.  Immunomodulatory spherical nucleic acids , 2015, Proceedings of the National Academy of Sciences.

[102]  Sadik H. Kassim,et al.  Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma , 2015, Clinical Cancer Research.

[103]  J. Wolchok,et al.  Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[104]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[105]  P Jack Hoopes,et al.  Local hyperthermia treatment of tumors induces CD8(+) T cell-mediated resistance against distal and secondary tumors. , 2014, Nanomedicine : nanotechnology, biology, and medicine.

[106]  H. Kohrt,et al.  Intratumoral Immunization: A New Paradigm for Cancer Therapy , 2014, Clinical Cancer Research.

[107]  J. Hubbell,et al.  Enhancing Efficacy of Anticancer Vaccines by Targeted Delivery to Tumor-Draining Lymph Nodes , 2014, Cancer Immunology Research.

[108]  R. Vonderheide,et al.  Mitigating the toxic effects of anticancer immunotherapy , 2014, Nature Reviews Clinical Oncology.

[109]  Gregory L. Szeto,et al.  Structure-based programming of lymph-node targeting in molecular vaccines , 2014, Nature.

[110]  Michael R. King,et al.  TRAIL-coated leukocytes that kill cancer cells in the circulation , 2014, Proceedings of the National Academy of Sciences.

[111]  Baran D. Sumer,et al.  A Broad Nanoparticle-Based Strategy for Tumor Imaging by Nonlinear Amplification of Microenvironment Signals , 2013, Nature materials.

[112]  J. Hubbell,et al.  Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response. , 2014, Biomaterials.

[113]  S. Abrams,et al.  Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy , 2014, Cancer Immunology, Immunotherapy.

[114]  R. Jain,et al.  Strategies for advancing cancer nanomedicine. , 2013, Nature materials.

[115]  Shyh-Dar Li,et al.  Docetaxel conjugate nanoparticles that target α-smooth muscle actin-expressing stromal cells suppress breast cancer metastasis. , 2013, Cancer research.

[116]  Darrell J Irvine,et al.  In vivo targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[117]  J. Hubbell,et al.  Peripherally Administered Nanoparticles Target Monocytic Myeloid Cells, Secondary Lymphoid Organs and Tumors in Mice , 2013, PloS one.

[118]  K Dane Wittrup,et al.  Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity. , 2013, Cancer research.

[119]  H. Maeda,et al.  The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. , 2013, Advanced drug delivery reviews.

[120]  Abhishek D. Garg,et al.  Immunogenic cell death and DAMPs in cancer therapy , 2012, Nature Reviews Cancer.

[121]  Richard A Flavell,et al.  Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. , 2012, Nature materials.

[122]  R. Xavier,et al.  Bacille Calmette-Guérin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes , 2012, Proceedings of the National Academy of Sciences.

[123]  R. Xavier,et al.  Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes. , 2012, Cell host & microbe.

[124]  D. Irvine,et al.  Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles. , 2012, Biomaterials.

[125]  M. Albert,et al.  Preexisting BCG-Specific T Cells Improve Intravesical Immunotherapy for Bladder Cancer , 2012, Science Translational Medicine.

[126]  D. Irvine,et al.  Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy. , 2011, Biomaterials.

[127]  Darrell J Irvine,et al.  Enhancing Cell therapies from the Outside In: Cell Surface Engineering Using Synthetic Nanomaterials. , 2011, Nano today.

[128]  Martin F. Bachmann,et al.  Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns , 2010, Nature Reviews Immunology.

[129]  G. Trinchieri,et al.  Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. , 2010, Cancer research.

[130]  Dai Fukumura,et al.  A nanoparticle size series for in vivo fluorescence imaging. , 2010, Angewandte Chemie.

[131]  Soong Ho Um,et al.  Therapeutic cell engineering using surface-conjugated synthetic nanoparticles , 2010, Nature Medicine.

[132]  D. Irvine,et al.  Engulfing tumors with synthetic extracellular matrices for cancer immunotherapy. , 2009, Biomaterials.

[133]  C. Grady,et al.  Points to consider , 2009 .

[134]  Yingqun Wang,et al.  Wnt/Planar cell polarity signaling: A new paradigm for cancer therapy , 2009, Molecular Cancer Therapeutics.

[135]  Warren C W Chan,et al.  Mediating tumor targeting efficiency of nanoparticles through design. , 2009, Nano letters.

[136]  J. A. van der Laak,et al.  Intratumoral rhIL‐12 administration in head and neck squamous cell carcinoma patients induces B cell activation , 2008, International journal of cancer.

[137]  Takeshi Shimizu,et al.  Nanogel DDS enables sustained release of IL-12 for tumor immunotherapy. , 2008, Biochemical and biophysical research communications.

[138]  H. Tsao,et al.  ‘Benchside‐to‐Bedside’ , 2007 .

[139]  K. Cornetta,et al.  Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene. , 2007, Blood.

[140]  Charles R. Martin.  Nanomedicine: a great first year and, with your help, a bright future ahead , 2007 .

[141]  S. Pun,et al.  Increased nanoparticle penetration in collagenase-treated multicellular spheroids , 2007, International journal of nanomedicine.

[142]  D. Munn,et al.  The tumor‐draining lymph node as an immune‐privileged site , 2006, Immunological reviews.

[143]  P. Low,et al.  Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma. , 2004, Cancer letters.

[144]  M. Choti,et al.  Controlled Local Delivery of Interleukin-2 by Biodegradable Polymers Protects Animals from Experimental Brain Tumors and Liver Tumors , 2001, Pharmaceutical Research.

[145]  Mark M. Davis,et al.  T-cell-antigen recognition and the immunological synapse , 2003, Nature Reviews Immunology.

[146]  R. B. Campbell,et al.  Role of tumor–host interactions in interstitial diffusion of macromolecules: Cranial vs. subcutaneous tumors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[147]  H. Honda,et al.  Antitumor Immunity Induction by Intracellular Hyperthermia Using Magnetite Cationic Liposomes , 1998, Japanese journal of cancer research : Gann.